Plixorafenib (PLX8394/FORE8394) treatment leads to sustained tumor regression in preclinical models of BRAF-mutated primary and brain metastatic melanoma

Press Release Nov 04 2025 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Event Oct 13 2025 FORE Biotherapeutics to Host Virtual Key Opinion Leader Roundtable Discussion on Plixorafenib’s Potential to Disrupt the BRAF Market to Benefit Patients Read more

Press Release Sep 24 2025 FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors Read more